Answer
Satralizumab’s terminal elimination half-life associated with linear clearance in patients with NMO or NMOSD at the recommended dose is approximately 30 days (range 22–37 days), based on pooled phase 3 study data.
Sources for this answer
- Enspryng 120 mg solution for injection in pre-filled syringeRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 3Document updated
Sources checked